Our mission is to accelerate drug discovery from decades to years and from months to days.
Building the future, caring for both human and animal lives. We are StemnovateTM .
Reprogramming and Differentiation
We are experts in cellular reprogramming and one of the only companies globally with the capability for human and animal reprogramming. We design vectors with an industrial process to generate induced pluripotent stem cells. For industry and academia, we routinely differentiate stem cells into the liver, heart, and neuronal cells.
READ MORE
Chip Technology
We are innovating organs-on-chip platforms to provide a physiological alternative to cancer lines and animal models for advanced drug discovery. From 2017 to 2019, our research was co-funded by Innovate UK to develop a liver on chip platform. This million-pound funding resulted in patenting innovation that we aim to launch to market soon.
View Products
Automation for drug discovery
The drug discovery data often cannot be reproduced with conventional techniques. Therefore, we integrate computational modelling and microengineering to enable next-gen drug development. Automation for preclinical research and development will save cost and time and revolutionize the pharmaceutical industry.
READ MOREHOW IT WORKS
In vitro Absorption, distribution, metabolism and excretion studies can be conducted on tissues showing multicellular interactions in microphysiological systems.
The multiparametric data obtained from cell studies, assays, protein and gene expression and imaging is used for data analysis and predictive modelling of drug response.
The quantitative data is obtained through biosensors for microenvironment changes and physiological parameter analysis.
Cytochrome P450 studies are complimented with metabolism assays, expression profiling and transcriptomic analysis. A comprehensive data to understand the mechanistic of action or toxicity.
In-depth studies for cell proliferation, apoptosis, receptors & transporters.
Microfluidic device development involves CAD design, 3D printing, prototyping following by application optimisation and manufacturing.
Pharmacogenetics allows the study of the genetic variation due to ethnicity and gender that affects their response or adverse reaction to
medicines or xenobiotics.
Stemnovate has diverse bank of IPS lines that represent the human variability for pharmacogenetics studies.
Our multispecies cellular models allow in vitro studies for mechanism of action, transporters and signalling pathways. This reduced animal testing while the models benefit veterinary drug development and disease modelling.
Cytochromes P450 (CYPs) are the main enzymes involved in drug metabolism. These show huge expression variability among humans. We study CYP inhibition, induction, expression and polymorphism.
Tissue consists of specialised cells functioning while uniquely organised. We simulate this organisation for microphysiological studies. Eg, Liver tissue consists of hepatocytes, stellate and Kupffer cells.
Partnerships
We have global partnerships that include top tier pharmaceutical companies and world-renowned academia. As a result, we have successfully delivered projects that incorporate innovation and integration of advanced microengineering and cellular technologies.
We have industrial partnerships on several PhD studentships with the National Physical Laboratory, the University of Edinburgh, the University of Northumbria, and the Babraham Institute, to name a few.
Stemnovate is certified as an ISO 9001: 2015 company. We have an experienced team of Phds and Postdocs from top institutes across the world, and hence are well equipped to overcome challenges in research and development.
